Table 2.
Association of EBER-EBV DNA combination and survival outcomes in patients with nasopharyngeal carcinoma in the entire cohort
| Characteristic | Non-adjusted | Model 1 | Model 2 | Model 3 | ||||
|---|---|---|---|---|---|---|---|---|
| HR (95% CI) | P value | HR (95% CI) | P value | HR (95% CI) | P value | HR (95% CI) | P value | |
| LRFFS | ||||||||
| EBER+/EBV DNA+ | 1.000 (Reference) | 1.000 (Reference) | 1.000 (Reference) | 1.000 (Reference) | ||||
| EBER+/EBV DNA- | 0.554 (0.302–1.017) | 0.057 | 0.566 (0.308–1.039) | 0.066 | 0.669 (0.361–1.241) | 0.202 | 0.700 (0.378–1.297) | 0.257 |
| EBER-/EBV DNA+ | 1.123 (0.359–3.512) | 0.842 | 1.194 (0.381–3.738) | 0.761 | 1.297 (0.413–4.069) | 0.656 | 1.194 (0.380–3.748) | 0.762 |
| EBER-/EBV DNA- | 4.368 (2.058–9.269) | < 0.001 | 4.713 (2.215–10.028) | < 0.001 | 3.357 (1.401–8.039) | 0.007 | 3.588 (1.486–8.659) | 0.004 |
| OS | ||||||||
| EBER+/EBV DNA+ | 1.000 (Reference) | 1.000 (Reference) | 1.000 (Reference) | 1.000 (Reference) | ||||
| EBER+/EBV DNA- | 0.424 (0.209–0.862) | 0.018 | 0.404 (0.198–0.821) | 0.012 | 0.522 (0.254–1.073) | 0.077 | 0.511 (0.248–1.050) | 0.068 |
| EBER-/EBV DNA+ | 1.441 (0.534–3.885) | 0.471 | 1.349 (0.500-3.642) | 0.555 | 1.632 (0.601–4.431) | 0.336 | 1.649 (0.606–4.490) | 0.328 |
| EBER-/EBV DNA- | 2.654 (0.987–7.142) | 0.053 | 2.442 (0.906–6.585) | 0.078 | 1.604 (0.542–4.749) | 0.394 | 1.632 (0.550–4.842) | 0.377 |
Model 1 was adjusted for age and gender
Model 2 was adjusted for age, gender, T category, N category, and histology
Model 3 was adjusted for age, gender, T category, N category, histology, induction and concurrent chemotherapy
EBER, EBV-encoded small RNA; EBV, Epstein-Barr virus; LRFFS, locoregional failure-free survival; OS, overall survival